Acute myeloid leukemia with FIP1-like-1-platelet-derived growth factor receptor α fusion gene positive progressed from idiopathic hypereosinophilic syndrome: report of one case and review of literature
10.3760/cma.j.issn.1009-9921.2019.10.004
- VernacularTitle: 特发性嗜酸性粒细胞增多综合征进展为FIP1样1血小板衍化生长因子受体α融合基因阳性急性髓系白血病一例并文献复习
- Author:
Yi WU
1
;
Kun YANG
2
;
Quan REN
1
;
Junhong CHEN
3
;
Tianhong ZHOU
3
;
Xiaolin YIN
3
Author Information
1. Graduate School of Guilin Medical College, Guilin 541004, China
2. Graduate School of Guangxi University of Chinese Medicine, Nanning 530200, China
3. Department of Hematology, the 923rd Hospital of the People's Liberation Army Joint Service Support Force, Nanning 530200, China
- Publication Type:Journal Article
- Keywords:
Hypereosinophilic syndrome;
Leukemia, myeloid, acute;
Gene fusion
- From:
Journal of Leukemia & Lymphoma
2019;28(10):593-595
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To improve the understanding of idiopathic hypereosinophilic syndrome (HES) and to be aware of its potential of transforming to acute myeloid leukemia (AML).
Methods:The clinical data of one patient diagnosed with HES progressed to AML in the 923rd Hospital of the People's Liberation Army Joint Service Support Force were analyzed, and relevant literatures were reviewed.
Results:The patient was diagnosed with idiopathic HES that progressed to AML with FIP1-like-1-platelet-derived growth factor receptor α (FIP1L1-PDGFRA) after 2 years. The patients achieved complete remission after the treatment of chemotherapy combined with tyrosine kinase inhibitor and then received hematopoietic stem cell transplantation. The patient had more than 1 year disease-free survival until the deadline.
Conclusion:Idiopathic HES has the potential to transform to AML with FIP1L1-PDGFRA fusion gene positive, therefore regular follow-up should be emphasized.
